YAP1 and osteosarcoma: Immunohistochemically, high YAP expression was noted in 60% to 85% of osteosarcomas [184,185,186,187], but only nuclear immunoreactivity in 30% to 46% of cases correlated with an adverse outcome (observed in some [184,185] but not all studies, potentially due to small patient cohorts [186,188]).